Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment (Q39984416)

16 September 2017

Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment (English)

1 reference

16 September 2017

Kenneth G Saag

1

1 reference

16 September 2017

Andrew Whelton

2

1 reference

16 September 2017

Michael A Becker

3

1 reference

16 September 2017

Patricia MacDonald

4

1 reference

16 September 2017

Barbara Hunt

5

1 reference

16 September 2017

Lhanoo Gunawardhana

6

1 reference

16 September 2017

language of work or name

1 reference

19 February 2016

1 reference

16 September 2017

Arthritis & Rheumatology

1 reference

16 September 2017

68

1 reference

16 September 2017

2035-2043

1 reference

16 September 2017

8

1 reference

Risk factors for end-stage renal disease: 25-year follow-up

16 September 2017

1 reference

Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects

21 January 2018

1 reference

Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease

21 January 2018

1 reference

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

Uric acid levels predict future development of chronic kidney disease

21 January 2018

1 reference

Association of uric acid with change in kidney function in healthy normotensive individuals

21 January 2018

1 reference

Reduced glomerular function and prevalence of gout: NHANES 2009-10

21 January 2018

1 reference

Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.

21 January 2018

1 reference

Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.

21 January 2018

1 reference

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

21 January 2018

1 reference

The influence of temperature on the solubility of monosodium urate

21 January 2018

1 reference

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

21 January 2018

1 reference

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

21 January 2018

1 reference

Preservation of renal function during gout treatment with febuxostat: a quantitative study

21 January 2018

1 reference

Renal function in gout: long-term treatment effects of febuxostat

21 January 2018

1 reference

Preliminary criteria for the classification of the acute arthritis of primary gout

21 January 2018

1 reference

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

Gout and its comorbidities: implications for therapy

21 January 2018

1 reference

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.39654

1 reference

16 September 2017

1 reference